{"id":11999,"date":"2021-10-25T14:29:36","date_gmt":"2021-10-25T12:29:36","guid":{"rendered":"https:\/\/eestiarst.ee\/en\/?p=11999"},"modified":"2021-10-25T14:29:36","modified_gmt":"2021-10-25T12:29:36","slug":"long-acting-glucagon-like-peptide-1-receptor-agonists","status":"publish","type":"post","link":"https:\/\/eestiarst.ee\/en\/long-acting-glucagon-like-peptide-1-receptor-agonists\/","title":{"rendered":"Long-acting glucagon- like peptide-1 receptor agonists"},"content":{"rendered":"<p>The use of long-acting glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of type 2 diabetes is on the rise. Right now, available drugs in Estonia are liraglutide, long acting exenatide (exenatide LAR), dulaglutide and semaglutide. Although most GLP1-RAs are used as subcutaneous injections, also a novel oral version of semaglutide is available. GLP1-RAs need to be administered once daily (liraglutide and oral semaglutide) or once weekly. Their advantage is a strong effect in lowering postprandial blood glucose levels, glycated haemoglobin (HbA1c) levels and body weight. Cardiovascular safety trials have also identified their positive effects in preventing cardiovascular events and all-cause mortality, which is why they are considered to be preferable treatment for patients with existing cardiovascular disease. The main adverse effects associated with GLP1-RAs are nausea, vomiting and diarrhoea. The gastrointestinal adverse effects usually subside with prolonged treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The use of long-acting glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of type 2 diabetes is on the rise. Right now, available drugs in Estonia are liraglutide, long acting exenatide (exenatide LAR), dulaglutide and semaglutide. Although most GLP1-RAs are used as subcutaneous injections, also a novel oral version of semaglutide is available. GLP1-RAs need &#8230;<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[1538],"class_list":["post-11999","post","type-post","status-publish","format-standard","hentry","category-articles","tag-review","authors-marta-kotkas","authors-vallo-volke"],"acf":[],"_links":{"self":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts\/11999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/comments?post=11999"}],"version-history":[{"count":1,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts\/11999\/revisions"}],"predecessor-version":[{"id":12000,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts\/11999\/revisions\/12000"}],"wp:attachment":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/media?parent=11999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/categories?post=11999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/tags?post=11999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}